Core Insights - EDAP TMS SA has initiated a phase I/II PULS Trial to evaluate High Intensity Focused Ultrasound (HIFU) technology for treating pancreatic tumors, marking a significant milestone in addressing this challenging disease [1][2] - The trial aims to assess the tolerance and preliminary efficacy of HIFU in patients with locally advanced and unresectable pancreatic tumors, highlighting the urgent need for new treatment options in this area [2][3] Company Overview - EDAP TMS SA is recognized as a leader in robotic energy-based therapies, developing and distributing minimally invasive medical devices utilizing ultrasound technology [4] - The company has introduced the Focal One system, which is a leading prostate focal therapy device, and is exploring its potential for multiple indications beyond prostate cancer [4] Industry Context - Pancreatic cancer has a five-year survival rate of only 11.5%, with an estimated 62,210 new cases and 49,830 deaths projected in the U.S. for 2022, making it one of the most difficult cancers to treat [3] - Despite a 5.5% improvement in the relative five-year survival rate over the past decade, pancreatic cancer remains the third leading cause of cancer deaths, underscoring the critical need for innovative treatment solutions [3]
EDAP Announces First Pancreatic Cancer Patient Treated with Proprietary HIFU Technology